These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37479613)

  • 21. Modified mRNA-Based Vaccines Against Coronavirus Disease 2019.
    Wang AYL
    Cell Transplant; 2022; 31():9636897221090259. PubMed ID: 35438579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2.
    Lee KM; Lin SJ; Wu CJ; Kuo RL
    Biomed J; 2023 Feb; 46(1):70-80. PubMed ID: 36642222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Critical Assessment of COVID-19 Genomic Vaccines.
    Sabbah DA; Hajjo R; Sunoqrot S
    Curr Top Med Chem; 2023; 23(27):2552-2589. PubMed ID: 37622697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations.
    Mirtaleb MS; Falak R; Heshmatnia J; Bakhshandeh B; Taheri RA; Soleimanjahi H; Zolfaghari Emameh R
    Int Immunopharmacol; 2023 Apr; 117():109934. PubMed ID: 36867924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in COVID-19 mRNA vaccine development.
    Fang E; Liu X; Li M; Zhang Z; Song L; Zhu B; Wu X; Liu J; Zhao D; Li Y
    Signal Transduct Target Ther; 2022 Mar; 7(1):94. PubMed ID: 35322018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of mRNA Vaccines/Therapeutics and Their Delivery System.
    Son S; Lee K
    Mol Cells; 2023 Jan; 46(1):41-47. PubMed ID: 36697236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studies.
    Lu J; Tan S; Gu H; Liu K; Huang W; Yu Z; Lu G; Wu Z; Gao X; Zhao J; Yao Z; Yi F; Yang Y; Wang H; Hu X; Lu M; Li W; Zhou H; Yu H; Shan C; Lin J
    Emerg Microbes Infect; 2024 Dec; 13(1):2321994. PubMed ID: 38377136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Messenger RNA vaccines for cancer immunotherapy: progress promotes promise.
    Huff AL; Jaffee EM; Zaidi N
    J Clin Invest; 2022 Mar; 132(6):. PubMed ID: 35289317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines.
    Wei J; Hui AM
    Cancer Treat Rev; 2022 Jun; 107():102405. PubMed ID: 35576777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. mRNA-Based Vaccines and Mode of Action.
    Gergen J; Petsch B
    Curr Top Microbiol Immunol; 2022; 440():1-30. PubMed ID: 33591423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The discovery and development of mRNA vaccines for the prevention of SARS-CoV-2 infection.
    Xue VW; Wong SCC; Li B; Cho WCS
    Expert Opin Drug Discov; 2023 Jul; 18(7):769-780. PubMed ID: 37237360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in mRNA vaccines.
    Li M; Wang Z; Xie C; Xia X
    Int Rev Cell Mol Biol; 2022; 372():295-316. PubMed ID: 36064266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic.
    Jain S; Venkataraman A; Wechsler ME; Peppas NA
    Adv Drug Deliv Rev; 2021 Dec; 179():114000. PubMed ID: 34637846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advancing mRNA technologies for therapies and vaccines: An African context.
    Kairuz D; Samudh N; Ely A; Arbuthnot P; Bloom K
    Front Immunol; 2022; 13():1018961. PubMed ID: 36353641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy.
    Deng Z; Tian Y; Song J; An G; Yang P
    Front Immunol; 2022; 13():887125. PubMed ID: 35720301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory responses than mRNA vaccines in human PBMCs, macrophages and moDCs.
    Jiang M; Väisänen E; Kolehmainen P; Huttunen M; Ylä-Herttuala S; Meri S; Österlund P; Julkunen I
    Vaccine; 2023 Jun; 41(26):3813-3823. PubMed ID: 37142461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges.
    Malik JA; Ahmed S; Mir A; Shinde M; Bender O; Alshammari F; Ansari M; Anwar S
    J Infect Public Health; 2022 Feb; 15(2):228-240. PubMed ID: 35042059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
    Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
    mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.